Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and DDI Study of Setanaxib
NCT04327089Phase 1Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of setanaxib in primary biliary cholangitis (PBC) (7 cohorts), sponsored by Calliditas Therapeutics AB. Primary endpoints: Dose proportionality of setanaxib tablets after single oral administration at 144 hours, Drug-drug interactions of multiple oral administrations of setanaxib at 14 days and 1 more. Started Jun 2020; status: completed.
02
Drugs
setanaxib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04327089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04327089.